$470M investments to guarantee made-in-Canada vaccine
@FP_Champagne @PattyHajdu @SanofiCanada
The Canadian and Ontario governments are giving $470 million to a French vaccine maker to ensure we aren’t stuck depending on distant foreign suppliers for vaccines whenever the next global pandemic arises.
The federal government will invest $415 million in the partnership with Sanofi Pasteur Ltd. Ontario’s government will contribute $55 million to the project. The company will also invest at least $79 million a year to fund Canadian research and development.
François-Philippe Champagne, Minister of Innovation, Science, and Industry, together with the Honourable Patty Hajdu, Minister of Health, announced the investment in building an end-to-end influenza vaccine manufacturing facility in Toronto, Ontario.
This new facility will ensure drug product formulation, fill-and-finish, and inspection. As part of this project, Sanofi will invest more than $455 million as well as create and maintain 1,225 highly skilled jobs in Canada, according to a press release.
After a global search, Sanofi has chosen Canada as the home of its international production and distribution centre for their high-dose seasonal influenza vaccine, FLUZONE® High Dose Quadrivalent Influenza Vaccine (FLUZONE® HD QIV).
In addition to creating jobs and funding Canadian research, this facility means better pandemic preparedness for all Canadians. In the event of a future flu outbreak, Sanofi will be able to manufacture pandemic influenza vaccine at a population scale at its new Toronto facility. It will have the capacity to produce enough vaccine doses to support the entire Canadian population within approximately six months of the World Health Organization (WHO) identifying a pandemic influenza strain.
“Today’s announcement demonstrates Canada’s ability to attract foreign investments and to develop facilities with made-in-Canada solutions. This once-in-a-generation investment shows our government’s commitment to rebuilding Canada’s domestic biomanufacturing sector, focusing on both short-term strategic solutions and a long–term vision. By investing in this project, our government is helping to keep expertise in Canada, creating and maintaining highly skilled jobs, and securing the health and safety of Canadians. By fostering an environment where companies can invest and grow, leading life sciences firms like Sanofi are increasingly looking to Canada to establish their manufacturing facilities,” Minister François-Philippe Champagne said.
“This major new investment in biomanufacturing is an important step forward for Canada. Building on our domestic capacity to produce pandemic influenza vaccine is all part of our commitment to protect the health and safety of all Canadians now and in the years to come,” said the health minister.